Skip to main content

Pancreatic Cancer Clinical Trials

Review the pancreatic cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 303

Radiation Therapy with Dual Immune Checkpoint Inhibitor Therapy (Botensilimab and Balstilimab) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma, Miami EMPIRE Trial
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Circulating Tumor DNA to Determine Early Switch From First-Line mFOLFIRINOX to Second-Line Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Comparing two Chemotherapy Regimens (NALIRIFOX and mGAP) in the Treatment of Locally Advanced, Unresectable, and Metastatic Pancreatic Adenocarcinoma
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Odetiglucan and Mitazalimab as Maintenance Therapy in Patients with Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
FOLFIRINOX Chemotherapy Before Surgery in Treating Patients with Non-Metastatic Pancreatic Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
iExosomes in Combination with Ipilimumab for the Treatment of Patients with Metastatic Pancreas Cancer with KrasG12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pegcetacoplan in Combination with Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
AGEN2373 in Combination with GVAX or mKRASvax for the Treatment of Patients with Stage I or II Resectable Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Immunotherapy (EGFR FPBMC) for the Treatment of Locally Advanced, Metastatic, or Unresectable Pancreatic Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Erlotinib, Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Basal-Like Pancreatic Cancer, PANGEA Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Gemcitabine and Nab-Paclitaxel With or Without ONT01 for the Treatment of Unresectable/Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intraperitoneal TROP2-CAR-NK for the Treatment of Patients with Platinum-Resistant High Grade Ovarian Cancer, Mesonephric-Like Adenocarcinoma and Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland